drug · small molecule
LENALIDOMIDE
Marketedupdated 5mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 66 investigational indications.
targets
CRL4(CRBN) E3 ubiquitin ligase
all catalysts(2)
Trials studying LENALIDOMIDE
- phase2Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
- phase3A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- phase3A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- phase22015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- phase2A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
- phase2Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
- phase1A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
- phase2Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 27, 2027
204 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Mar 8, 2028method-of-use (U-1983)US 87419291.4y
- Mar 8, 2028method-of-use (U-1983)US 87419291.4y
- Mar 8, 2028method-of-use (U-1983)US 87419291.4y
- Mar 8, 2028method-of-use (U-1983)US 87419291.4y
- Mar 8, 2028method-of-use (U-1983)US 87419291.4y
- Mar 8, 2028method-of-use (U-1983)US 87419291.4y
- Apr 27, 2027compositionUS 7465800204d
- Apr 27, 2027compositionUS 7465800204d
- Apr 27, 2027compositionUS 7465800204d
- Apr 27, 2027compositionUS 7465800204d
- Apr 27, 2027compositionUS 7465800204d
- Apr 27, 2027compositionUS 7465800204d
FDA exclusivities (12)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
News(10)
- Biogen's monoclonal antibody felzartamab wins first global approval in ChinaBiogen’s monoclonal antibody felzartamab was approved in China for the treatment of multiple myeloma. Felzartamab will be available in China for second-line multiple myeloma patients alongside lena…endpoints · 1mo ago
- Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from CelgeneThe clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.biopharma_dive · 1mo ago
- BMS welcomes new multiple myeloma drug as generics batter current portfolioThe FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in…biospace · 1mo ago
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca mergerWhile both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…biospace · 2mo ago
- BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delaysStrong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…biospace · 2mo ago
- Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beatInvestors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.fiercebiotech · 2mo ago
- Agenus surges on study pivot; Apnimed lines up an IPOAgenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.biopharma_dive · 2mo ago
- Bristol Myers unveils data for one of its next-gen blood cancer drugsCalled mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.biopharma_dive · 4mo ago
- CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineA Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.biopharma_dive · 5mo ago
- Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookInvestors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.biopharma_dive · 5mo ago
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that